Zepbound® (tirzepatide) is used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
Do not use Zepbound® (tirzepatide) if:
You can take Zepbound® with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your provider will guide you on a treatment regimen that may include an increase in dose every four weeks.
You should not change your dosing regimven or stop taking Zepbound® (tirzepatide) as prescribed without discussing with your provider first.
In particular, tell your provider if you have a past history of:
Pregnancy registry: There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Zepbound® (tirzepatide) during pregnancy. Pregnant patients exposed to Zepbound® (tirzepatide) and healthcare providers are encouraged to contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).
Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death.
If you are experiencing a medical emergency, call 911 or seek immediate medical attention.
These serious side effects are rare, but can occur with Zepbound® (tirzepatide). You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dose changes.
You are encouraged to report negative side effects of prescription products to the FDA.
Visit fda.gov/medwatch or call 1-800-FDA-1088.
Disclaimer: Ozempic®, WeGovy®, Saxenda® and Victoza® are registered trademarks of Novo Nordisk. Zepbound® and Mounjaro® are registered trademarks of Eli Lilly. Byetta® and Bydureon® are registered trademarks of Amylin Pharmaceuticals. Brightmeds has no affiliation with Novo Nordisk, Eli Lilly or Amylin Pharmaceuticals. The compounded products available as part of our Weight Loss Program are not made by Novo Nordisk, Eli Lilly or Amylin Pharmaceuticals or any company affiliated with Novo Nordisk, Eli Lilly or Amylin Pharmaceuticals.
1 In a clinical trial , the participants with BMI 30 or more, or 27 or more with at least one weight-related condition, the average participant lost 20.9% of body weight during the 72-week trial.
2 In a clinical trial , the participants with BMI 30 or more, or 27 or more with at least one weight-related condition, the average participant lost 14.9% of body weight during the 68-week trial.
Weight loss study results like the above may vary for oral semaglutide due to potential differences in formulation and dosing. Licensed medical professionals, including Brightmeds-affiliated physicians, can prescribe oral semaglutide after medical evaluation to aid in weight management. For personalized guidance, we recommend consulting with a healthcare provider.
*Important Notice: The recognized brand name medication approved by the FDA, Zepbound™ and Mounjaro® is manufactured by Eli Lilly and Company™, and Wegovy® and Ozempic® is manufactured by Novo Nordisk™. We do NOT manufacture this medication and have no direct affiliation with either Eli Lilly and Company™or Novo Nordisk™. Upon patient request, our partner pharmacies can supply the above mentioned brand name medication, however they are subject to availability.
Regarding compounded medications, our company works with sterile compounding pharmacies. These facilities undergo strict inspections, but because the compounded pharmaceuticals they produce are made according to a prescription from a specific practitioner for a particular patient, they are not FDA-approved. It might be challenging to directly compare the results and risk profiles of FDA-approved and compounded pharmaceuticals due to differences in strength, dose, and other factors. The medical judgment of a licensed clinician, based on a telemedicine interaction and medical history, determines the prescription of any compounded medication.
100% money back guarantee if your prescription is not approved; brightmeds.com does not directly offer medical or pharmacy services. We partner with medical professionals who use HIPAA-compliant platforms to deliver services. This website’s content is meant only as a source of information; it should not be used as a substitute of expert medical advice, evaluation, or care. Please contact your doctor if you have any questions or concerns regarding your health.
Copyright 2024 Brightmeds.com